title: Heir to the throne or young pretender: can targeted therapy added to gemcitabine-cisplatin doublet therapy improve outcomes for advanced urothelial cancer?
authors.affiliation: Rosemere Cancer Centre Royal Preston Hospital, Preston, Lancashire, UK. Electronic address: Alison.birtle@lthtr.nhs.
authors.forename: Alison
authors.initials: A
authors.lastname: Birtle
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000633:toxicity*; D001855:Bone Marrow Diseases / Q000139:chemically induced*; D002945:Cisplatin / Q000627:therapeutic use*; D003841:Deoxycytidine / Q000031:analogs & derivatives*; D005260:Female; D006801:Humans; D007211:Indoles / Q000633:toxicity*; D008297:Male; D011758:Pyrroles / Q000633:toxicity*; D014571:Urologic Neoplasms / Q000188:drug therapy*
chemical_list: D007211:Indoles; D011758:Pyrroles; D003841:Deoxycytidine; D002945:Cisplatin